Stocks · News reference

Hyperfine Announces Completion Of Enrollment In Contrast PMR Study Of Swoop Portable MRI; Plans FDA 510(k) Submission By End Of 2026 For First Indication Expansion

Sep 15, 2026, 12:16 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 9:24 AMBenzinga Insights
Full Transcript: Hyperfine Q2 2026 Earnings Call
Hyperfine (NASDAQ:HYPR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
HYPR
BenzingaOct 8, 2026, 1:02 PMBenzinga Newsdesk
Hyperfine shares are trading lower after the company reported its preliminary Q3 financial results and affirmed its FY26 sales guidance with its midpoint above estimates.
HYPR
SEC EDGAROct 8, 2026, 11:40 AMSEC EDGAR
8-K filing — Hyperfine, Inc. (HYPR)
Filed: 2026-10-08 AccNo: 0001193125-26-417437 Size: 9 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
HYPR
BenzingaOct 8, 2026, 11:38 AMBenzinga Newsdesk
Hyperfine Affirms FY2026 Sales Guidance of $20.000M-$22.000M vs $20.163M Est
Hyperfine (NASDAQ:HYPR) affirms FY2026 sales outlook from $20.000 million-$22.000 million to $20.000 million-$22.000 million vs $20.163 million estimate.
HYPR